BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $1.54 billion. The enterprise value is $2.01 billion.
Important Dates
The next confirmed earnings date is Monday, November 3, 2025, before market open.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 210.53 million shares outstanding. The number of shares has increased by 3.62% in one year.
| Current Share Class | 210.53M |
| Shares Outstanding | 210.53M |
| Shares Change (YoY) | +3.62% |
| Shares Change (QoQ) | +2.15% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 92.01% |
| Float | 196.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.11 |
| PS Ratio | 2.70 |
| Forward PS | 2.33 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 96.91 |
| P/OCF Ratio | 90.82 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 34.29, with an EV/FCF ratio of 127.29.
| EV / Earnings | n/a |
| EV / Sales | 3.60 |
| EV / EBITDA | 34.29 |
| EV / EBIT | 36.17 |
| EV / FCF | 127.29 |
Financial Position
The company has a current ratio of 2.25
| Current Ratio | 2.25 |
| Quick Ratio | 1.98 |
| Debt / Equity | n/a |
| Debt / EBITDA | 12.17 |
| Debt / FCF | 46.88 |
| Interest Coverage | 0.59 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 7.46% |
| Return on Invested Capital (ROIC) | 10.01% |
| Return on Capital Employed (ROCE) | 19.81% |
| Revenue Per Employee | $961,217 |
| Profits Per Employee | -$61,571 |
| Employee Count | 580 |
| Asset Turnover | 1.20 |
| Inventory Turnover | 39.36 |
Taxes
In the past 12 months, BCRX has paid $3.52 million in taxes.
| Income Tax | 3.52M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.25% in the last 52 weeks. The beta is 1.05, so BCRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -10.25% |
| 50-Day Moving Average | 7.64 |
| 200-Day Moving Average | 8.44 |
| Relative Strength Index (RSI) | 51.42 |
| Average Volume (20 Days) | 6,846,816 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BCRX had revenue of $557.51 million and -$35.71 million in losses. Loss per share was -$0.18.
| Revenue | 557.51M |
| Gross Profit | 370.64M |
| Operating Income | 55.46M |
| Pretax Income | -32.19M |
| Net Income | -35.71M |
| EBITDA | 58.51M |
| EBIT | 55.46M |
| Loss Per Share | -$0.18 |
Full Income StatementBalance Sheet
The company has $260.04 million in cash and $738.92 million in debt, giving a net cash position of -$478.88 million or -$2.27 per share.
| Cash & Cash Equivalents | 260.04M |
| Total Debt | 738.92M |
| Net Cash | -478.88M |
| Net Cash Per Share | -$2.27 |
| Equity (Book Value) | -421.59M |
| Book Value Per Share | -2.01 |
| Working Capital | 221.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $16.82 million and capital expenditures -$1.06 million, giving a free cash flow of $15.76 million.
| Operating Cash Flow | 16.82M |
| Capital Expenditures | -1.06M |
| Free Cash Flow | 15.76M |
| FCF Per Share | $0.07 |
Full Cash Flow StatementMargins
Gross margin is 66.48%, with operating and profit margins of 9.95% and -6.41%.
| Gross Margin | 66.48% |
| Operating Margin | 9.95% |
| Pretax Margin | -5.77% |
| Profit Margin | -6.41% |
| EBITDA Margin | 10.49% |
| EBIT Margin | 9.95% |
| FCF Margin | 2.83% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.62% |
| Shareholder Yield | -3.62% |
| Earnings Yield | -2.34% |
| FCF Yield | 1.03% |
Dividend DetailsAnalyst Forecast
The average price target for BCRX is $19.55, which is 167.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.55 |
| Price Target Difference | 167.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 14.20% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -2.05 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.05 |
| Piotroski F-Score | 6 |
